Molecular markers in endometrial hyperplasia

CME Journal of Gynecologic Oncology

Volumn 11, Issue 1 PART 1, 2006, Pages 61-67

  Atasoy, Pýnar ^a,b   Bozdoǧan, Önder ^a  

^a KIRIKKALE UNIVERSITY   (Turkey)

^b NONE   (Turkey)

Author keywords

Endometrium; Hyperplasia; Molecular markers

Indexed keywords

ANDROGEN RECEPTOR; APC; BETA CATENIN; CATHEPSIN D; CYCLIN A; CYCLIN D1; EPIDERMAL GROWTH FACTOR; ESTROGEN RECEPTOR; GENOMIC DNA; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; INTERLEUKIN 1BETA; MATRIX METALLOPROTEINASE; MOLECULAR MARKER; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; SOMATOMEDIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR ALPHA;

CANCER GROWTH; CARCINOGENESIS; CELL CYCLE REGULATION; CELL PROLIFERATION; CHROMOSOME 10; DISEASE CLASSIFICATION; DISEASE COURSE; DNA REPAIR; ENDOMETRIUM HYPERPLASIA; GENE INACTIVATION; GENE MUTATION; GROWTH INHIBITION; HUMAN; METHYLATION; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

EID: 35948940145     PISSN: 12199087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Ronnet BM, Kurman RJ. Precursor lesions of endometrial carcinoma. In: Kurman RJ, eds. Blaustein's Pathology of the Female Genital Tract, 5th edn. New York: Springer Verlag, 2002:467-500
2. Kumar V, Abbas AK, Fausto N. Neoplasia. Pathologic Basis of Disease. 7th edn. Philadelphia, The Elsevier Company, 2005;269-342
3. Mylonas I, Makovitzky J, Shabani, et al. Parathyroid hormone-related peptide (PTH-rp) in normal, hyperplastic and malignant endometrial tissue: an immunohistochemical analysis. Anticancer Res 2005;25:1633-1638
4. Hoshi S, Morimoto T, Saito H, Ichizuka K, Matsuoka R, YanaiharaT and Okai T: PTHrpP and PTH/PTHrp receptor expressions in human endometrium. Endocr J 2001; 48:219-225
5. Sukhikh GT, Zhdanov V, Davydova MP, et al. Disorders in cytokine gene expression in endometrial hyperplasia and effect on hormone therapy. Bull Exp Biol Med 2005;139(2):235-237
6. Mylonas I, Makovitzky J, Shabani, et al. Leukemia inhibitory factor (LIF) is immunohistochemically expressed in normal, hyperplastic and malignant endometrial tissue. Eur J Obstet Gynecol 2005;118:101-08
7. Hu K, Zhong G, He F. Expression of estrogen receptors ERα and ERβ in endometrial hyperplasia and adenocarcinoma. Int J Gynecol Cancer 2005;15:537-541
8. Bozdoǧan Ö, Atasoy P, Erekul S, Bozdoǧan N, Bayram M. Apoptosis related proteins and steroid hormone receptors in normal, hyperplastic and neoplastic endometrium. Int J Gynecol Pathol 2002;21:375-382
9. Ito K, Suzuki T, Akahira J, et al. Expression of androgen receptor and 5α-reductases and its disorders. Int J Cancer 2002;99:652-657
10. Mutter GL, Wada H, Faquin WC, et al. K-ras mutations appear in the premalignant phase of both microsatellite stable and unstable endometrial carcinogenesis. J Clin Pathol 1999;52:257-262
11. Lax SF. Molecular genetic pathways in various types of endometrial carcinomas. Virchows Arch 2004;444:213-223
12. Sun H, Enomoto T, Shroyer KR, et al. Clonal analysis and mutations in the PTEN and the K-ras genes in endometrial hyperplasia. Diag Mol Pathol 2002;11(4):204-211
13. Sasaki H, Nishii H, Takahashi H, et al. Mutations of the Ki-ras protooncogene in human endometrial hyperplasia and carcinoma. Cancer Res 1993;53:1906-1910
14. Feng YZ, Shiozawa T, Miyamoto T, Kashima H, Kurai M, Suzuki A, Konishi I. BRAF mutation in endometrial carcinoma and hyperplasia: correlation with KRAS and p53 mutations and mismatch repair protein expression. Clin Cancer Res 2005;11(17):6133-8
15. Bircan S, Ensari A, Öztürk S, et al. Immunohistochemical analysis of c-myc, c-jun and estrogen receptor in normal, hyperplastic and neoplastic endometrium. Pathol Oncol Res 2005;11(1):32-39
16. Bai MK, Costopoulos JS, Christoforidou BP, Papadimitriou CS. Immunohistochemical detection of the c-myc oncogene product in normal, hyperplastic and carcinomatous endometrium. Oncology. 1994;51(4):314-9
17. Kyushima N, Watanabe J, Hata H, Jobo T, Kameya T, Kuramoto H. Expression of cyclin A in endometrial adenocarcinoma and its correlation with proliferative activity and clinicopathological variables. J Cancer Res Clin Oncol. 2002 Jun;128(6):307-12
18. Susini T, Massi D, Paglierani M, Masciullo V, Scambia G, Giordano A, Amunni G, Massi G, Taddei GL Expression of the retinoblastoma-related gene Rb2/p130 is downregulated in atypical endometrial hyperplasia and adenocarcinoma. Hum Pathol 2001;32(4):360-7
19. Ozuysal S, Ozturk H, Bilgin T, Filiz G. Expression of cyclin D1 in normal, hyperplastic and neoplastic endometrium and its correlation with Ki-67 and clinicopathological variables. Arch Gynecol Obstet. 2005 Feb;271(2):123-6
20. Quddus MR, Latkovich P, Castellani WJ, et al. Expression of cyclin D1 in normal, metaplastic, hyperplastic endometrium and endometrioid carcinoma suggests a role in endometrial carcinogenesis. Arch Pathol Lab Med. 2002 Apr;126(4):459-463
21. Zukerberg LR, DeBernardo RL, Kirley SD, D'Apuzzo M, Lynch MP, Littell RD, Duska LR, Boring L, Rueda BR. Loss of cables, a cyclin-dependent kinase regulatory protein, is associated with the development of endometrial hyperplasia and endometrial cancer.Cancer Res. 2004;64(1):202-8
22. Jiko K, Sasano H, Ito K, et al. Immunohistochemical and in situ hybridization analysis of p53 in human endometrial carcinoma of the uterus. Anticancer Res 1993;13:305-310
23. Moreno-Bueno G, Hardisson D, Sarrio D, Sanchez C, Cassia R, Prat J, Herman JG, Esteller M, Matias-Guiu X, Palacios J. Abnormalities of E- and P-cadherin and catenin (beta-, gamma-catenin, and p120ctn) expression in endometrial cancer and endometrial atypical hyperplasia. J Pathol 2003;199(4):471-8
24. Seagusa M, Hashimura M, Yoshida T, et al. ?-catenin mutations and aberrant nuclear expression during endometrial tumorigenesis. Br J Cancer 2001;84(2):209-217
25. An HJ, Lee YH, Cho NH, Shim JY, Kim JY, Lee C, Kim SJ. Alteration of PTEN expression in endometrial carcinoma is associated with down-regulation of cyclin-dependent kinase inhibitor, p27. Histopathology. 2002 Nov;41(5):437-45
26. Sun H, Enomoto T, Fujita M, Wada H, Yoshino K, Ozaki K, Nakamura T, Murata Y. Mutational analysis of the PTEN gene in endometrial carcinoma and hyperplasia. Am J Clin Pathol. 2001;115(1):32-8
27. Matias-Guiu X, Catasus L, Bussaglia E, Lagarda H, Garcia A, Pons C, Munoz J, Arg Molecular pathology of endometrial hyperplasia and carcinoma. Hum Pathol. 2001;32(6):569-77
28. Ørbo A, Kaino T, Arnes M, et al. Genetic derangements in the tumor suppressor gene PTEN in endometrial precancers as prognostic markers for cancer development: a population-based study from northern Norway with long-term follow-up. Gynecol Oncol 2004,95:82-88
29. Holtz D, Ramondetta LM, Burke TW, Palazzo JP, Dunton CJ, Atkinson EN, Broaddus RR. PTEN expression in tamoxifen-associated endometrial cancers. Anticancer Res. 2002;22(5):2945-2948
30. Mutter GL, Lin MC, Fitzgerald JT, Kum JB, Baak JP, Lees JA, Weng LP, Eng C. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst. 2000;92(11):924-30
31. Atasoy P, Bozdogan O, Erekul S, Bozdogan N, Bayram M. Fas-mediated pathway and apoptosis in normal, hyperplastic, and neoplastic endometrium. Gynecol Oncol 2003;91(2):309-317
32. Kokowa K, Shikone T, Otani T, et al. Apoptosis and the expression of Bax and Bcl-2 in hyperplasia and adenocarcinoma of the uterine endometrium. Hum Rep 2001, 16(11):2211-2218
33. Levine RL, Cargile CB, Blazes MS, van Rees B, Kurman RJ, Ellenson LH. PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrioid carcinoma. Cancer Res. 1998;58(15):3254-3258
34. Cohn DE, Mutch DG, Herzog TJ, et al. Genotypic and phenotypic progression in endometrial tumorigenesis: determining when defects in DNA mismatch repair and KRAS2 occur. Genes, Chromosomes and Cancer 2001;32:295-301
35. Mutter GL, Boynton KA, Faquin WC, Ruiz RE, Jovanovic AS. Allelotype mapping of unstable microsatellites establishes direct lineage continuity between endometrial precancers and cancer. Cancer Res. 1996 Oct 1;56(19):4483-4486
36. Sutter C, Dallenbach-Hellweg G, Schmidt D, et al. Molecular analysis of endometrial hyperplasia in HNPCC-suspicious patients may predict progression to endometrial carcinoma. Int J Gynecol Pathol 2003;23:18-25
37. Horowitz N, Pinto K, Mutch DG, et al. Microsatellite instability, MLH-1 promoter methylation, and loss of mismatch repair in endometrial cancer and concomitant atypical hyperplasia. Gynecol Oncol 2002;86:62-68
38. Esteller M, Catasus L, Matias-Guiu X, Mutter GL, Prat J, Baylin SB, Herman JG. hMLH1 promoter hypermethylation is an early event in human endometrial tumorigenesis. Am J Pathol. 1999;155(5):1767-72
39. Vassivela V, Millar A, Brioallis, et al. Genes involved in DNA repair are mutational targets in endometrial cancers with microsatellite instability. Cancer Res 2002; 62(14):4095-4099
40. Hardisson D, Moreno-Bueno G, Sanchez L, et al. Tissue microarray immunohistochemical expression analysis of mismatch repair (hMLH1 and hMSH2 genes) in endometrial carcinoma and atypical endometrial hyperplasia: relationship with microsatellite instability. Mod Pathol 2003;16(11):1148-1158
41. Brustmann H. Immunohistochemical detection of human telomerase reverse transcriptase (hTERT), topoisomerase IIα expression, and apoptosis in endometrial adenocarcinoma and atypical hyperplasia. Int J Gynecol Pathol 2005;24:184-192
42. Ioachim E, Kitsiou E, Charalabopoulos K, Mitselou A, Zagorianakou N, Makrydimas G, Tzioras S, Salmas M. Immunohistochemical evaluation of cathepsin D in normal, hyperplastic and malignant endometrium: correlation with hormone receptor status c-erbB-2, p53, Rb proteins and proliferation associated indices. Int J Gynecol Cancer. 2003;13(3):344-51
43. Mylonas I, Makovitzky J, Richter DU, Jeschke U, Briese V, Friese K. Cathepsin D expression in normal, hyperplastic and malignant endometrial tissue: an immunohistochemical analysis. Acta Histochem. 2003;105(3):245-52
44. Isaka K, Nishi H, Nakai H, Nakada T, Feng Li Y, Ebihara Y, Takayama M. Matrix metalloproteinase-26 is expressed in human endometrium but not in endometrial carcinoma. Cancer. 2003 Jan 1;97(1):79-89
45. Maatta M, Soini Y, Liakka A, et al. Localization of MT-1-MMP, TIMP-1, TIMP-2, and TIMP-3 messenger RNA in normal, hyperplasti, and neoplastic endometrium. Am J Clin Pathol 2000;114:402-411
46. Pilka R, Domanski H, Hansson S et al. Endometrial TIMP-4mRNA is high at midcycle and in hyperplasia, but down-regulated in malignant tumors. Coordinated expression with MMP-26. Mol Hum Rep 2004;10(9):641-650
47. Zhang J, Cao YJ, Zhao YG, Sang QX, Duan EK. Expression of matrix metalloproteinase-26 and tissue inhibitor of metalloproteinase-4 in human normal cytotrophoblast cells and a choriocarcinoma cell line, JEG-3. Mol Hum Reprod. 2002 Jul;8(7):659-666